全文获取类型
收费全文 | 635篇 |
免费 | 67篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 39篇 |
妇产科学 | 10篇 |
基础医学 | 54篇 |
口腔科学 | 21篇 |
临床医学 | 120篇 |
内科学 | 151篇 |
皮肤病学 | 40篇 |
神经病学 | 15篇 |
特种医学 | 101篇 |
外科学 | 65篇 |
综合类 | 12篇 |
预防医学 | 22篇 |
眼科学 | 3篇 |
药学 | 13篇 |
肿瘤学 | 44篇 |
出版年
2023年 | 8篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 8篇 |
2018年 | 15篇 |
2017年 | 15篇 |
2016年 | 24篇 |
2015年 | 18篇 |
2014年 | 31篇 |
2013年 | 29篇 |
2012年 | 13篇 |
2011年 | 17篇 |
2010年 | 30篇 |
2009年 | 50篇 |
2008年 | 15篇 |
2007年 | 13篇 |
2006年 | 21篇 |
2005年 | 17篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 7篇 |
2001年 | 8篇 |
2000年 | 4篇 |
1999年 | 11篇 |
1998年 | 33篇 |
1997年 | 34篇 |
1996年 | 36篇 |
1995年 | 26篇 |
1994年 | 24篇 |
1993年 | 29篇 |
1992年 | 6篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 12篇 |
1987年 | 19篇 |
1986年 | 11篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1981年 | 9篇 |
1980年 | 5篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1965年 | 1篇 |
1963年 | 2篇 |
排序方式: 共有711条查询结果,搜索用时 15 毫秒
111.
IMMUNOLOGICAL FEATURES OF HLA-B27 ANTERIOR UVEITIS 总被引:2,自引:0,他引:2
DENIS WAKEFIELD FRACP FRCPA JOAN EASTER BSc MT PAUL ROBINSON MSC RONALD PENNY DSC FRACP FRCPA 《Clinical & experimental ophthalmology》1983,11(1):15-19
Analysis ol the immunological features of anterior Uveitis (AU) revealed a dichotomy of abnormalities defined in terms of the HLA-B27 status of the patient. HLA-B27-positive AU was characterised by the occurrence of ins autoantibodies and an absolute T cell lymphopenia during active disease which returned to normal with recovery. This phenomenon was not observed in HLA-B27-negative AU or in controls and could not be attributed to antilymphocyte antibodies as these were not detected. Furthermore, there were no changes in T-cell subsets (helper and suppressor T lymphocytes). Compared with HLA-B27-positive AU patients, the HLA-B27-negative group demonstrated elevated lgE levels and increased prevalence of smooth muscle autoantibodies. Key words: anterior Uveitis, HLA-B27, immunological abnormalities, T lymphocytes, autoantibodies. 相似文献
112.
113.
Gray-scale ultrasonography of the normal female pelvis 总被引:5,自引:0,他引:5
114.
Pedro J. Marín Aurora Martín-López Davinia Vicente-Campos MT Angulo-Carrere Teresa García-Pastor Nuria Garatachea José L. Chicharro 《Journal of Sports Science and Medicine》2011,10(3):559-564
The purpose of this study was to analyze the effects of 2 days/week versus 4 days/week of Whole Body Vibration (WBV) during eight weeks of WBV training on health-related quality of life (SF-36), balance and lower body strength, as well as short-term detraining (3 weeks) on balance and lower body strength among older adults. Thirty-four older adults were randomly assigned to a control group (Control; n = 11) or to one of the vibration training groups: WBV 2 days/week (WBV_2d; n = 11) or WBV 4 days/week (WBV_4d; n = 12). The WBV groups exercised for 8 weeks, following 3 weeks of detraining. Lower body strength increased significantly (p < 0.05) for both groups, WBV_2d and WBV_4d, after 8-week training. A significant reduction in strength was observed following 3 weeks of detraining only in WBV_2d group (p < 0.05). All variables of the SF-36 and the balance test did not change after intervention in any group. 2 days/week and 4 days/week of WBV during 8 weeks showed the same improvements on muscle strength. 3 weeks of detraining did not reverse the gains in strength made during 32 sessions of WBV.
Key points
- 2 days and 4 days per week of WBV training during 8 weeks showed the same improvements on muscle strength.
- 3 weeks of detraining did not reverse the gains in strength made during 32 sessions of WBV exercise.
- 3 weeks of detraining did reverse the gains in strength made during 16 sessions of WBV exercise.
115.
Min‐Jung Song MD Eun‐Hyung Yoo MD Ki‐O Lee MT Gee‐Na Kim MD Hee‐Jin Kim MD PhD Sun‐Young Kim MD Sun‐Hee Kim MD PhD 《Pediatric blood & cancer》2010,54(4):629-631
Diamond‐Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by pure red cell aplasia, various congenital anomalies, and cancer predisposition. We report a novel mutation in the RPS17 gene in a Korean patient with DBA. The mutation occurred in the translation initiation codon, changing Atg to Gtg (c.1A>G), thus disrupting the natural start of the RPS17 protein biosynthesis. This is the third case of DBA from a RPS17 mutation in the literature and is the second case of a RPS17 mutation in the translation initiation codon, following c.2T>G. Pediatr Blood Cancer 2010;54:629–631. © 2009 Wiley‐Liss, Inc. 相似文献
116.
Sweta Gupta MBBS MD Cindy L. Piefer MT SBB Judy T. Fueger MT SBB Susan T. Johnson MSTM MT SBB Rowena C. Punzalan MD 《Pediatric blood & cancer》2010,55(6):1201-1203
A 10‐year‐old male with acute leukemia presented with post‐chemotherapy anemia. During red cell transfusion, he developed hemoglobinuria. Transfusion reaction workup was negative. Drug‐induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre‐ and post‐transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim–sulfamethoxazole but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse‐than‐expected anemia after chemotherapy. Furthermore, hemolysis during transfusion is not always a transfusion reaction. Pediatr Blood Cancer. 2010;55:1201–1203. © 2010 Wiley‐Liss, Inc. 相似文献
117.
Hiroyuki Isayama Yousuke Nakai MD PhD Yoshihide Toyokawa MT Osamu Togawa MD Chimyon Gon MT Yukiko Ito MD Yoko Yashima MD Hiroshi Yagioka MD Hirofumi Kogure MD Takashi Sasaki MD Toshihiko Arizumi MD Saburo Matsubara MD Natsuyo Yamamoto MD PhD Naoki Sasahira MD PhD Kenji Hirano MD PhD Takeshi Tsujino MD PhD Nobuo Toda MD PhD Minoru Tada MD PhD Takao Kawabe MD PhD Masao Omata MD PhD 《Gastrointestinal endoscopy》2009,70(1):37-44
118.
119.
Richard E. Pratley MD Thérèse McCall PhD Penny R. Fleck MT Craig A. Wilson PhD Qais Mekki MD PhD 《Journal of the American Geriatrics Society》2009,57(11):2011-2019
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, in elderly (≥65) and younger (<65) patients with type 2 diabetes mellitus.
DESIGN: Pooled analysis of six randomized, double-blind, placebo-controlled studies of alogliptin.
PARTICIPANTS: Patients aged 18 to 80 with type 2 diabetes mellitus and inadequate glycemic control.
INTERVENTIONS: Elderly (mean age 70.0; n=455) and younger (mean age 51.8; n=1,911) patients received alogliptin 12.5 mg (n=922), alogliptin 25 mg (n=910), or placebo (n=534) for 26 weeks (12 weeks in a Phase 2 study). The studies evaluated alogliptin as monotherapy and coadministered with pioglitazone, glyburide, metformin, or insulin.
MEASUREMENTS: Efficacy endpoints included change from baseline in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), weight, and lipid values. Safety variables included hypoglycemic events, adverse events, and blood pressure.
RESULTS: Least-squares mean HbA1c decreased from baseline by 0.7% and 0.8% in elderly patients receiving alogliptin 12.5 and 25 mg, respectively, and 0.5% and 0.6%, respectively, in younger patients ( P <.001 for both alogliptin doses vs placebo for both age groups P =.70 for 12.5 mg and .68 for 25 mg for differences between age groups). Results were similar for FPG. Incidence of hypoglycemia was 8.3% or less in all alogliptin groups (≤10.5% for placebo), with no apparent difference between elderly and younger patients. Changes in weight were negligible in all treatment groups in both age categories. The safety profiles of alogliptin were similar in the age and dose groups.
CONCLUSION: Alogliptin was effective and well tolerated in the elderly patients enrolled in these studies. Improvements in HbA1c were similar to those seen in younger patients, and no increase in the risk of hypoglycemia, weight gain, or other adverse events was apparent in elderly patients. 相似文献
DESIGN: Pooled analysis of six randomized, double-blind, placebo-controlled studies of alogliptin.
PARTICIPANTS: Patients aged 18 to 80 with type 2 diabetes mellitus and inadequate glycemic control.
INTERVENTIONS: Elderly (mean age 70.0; n=455) and younger (mean age 51.8; n=1,911) patients received alogliptin 12.5 mg (n=922), alogliptin 25 mg (n=910), or placebo (n=534) for 26 weeks (12 weeks in a Phase 2 study). The studies evaluated alogliptin as monotherapy and coadministered with pioglitazone, glyburide, metformin, or insulin.
MEASUREMENTS: Efficacy endpoints included change from baseline in glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), weight, and lipid values. Safety variables included hypoglycemic events, adverse events, and blood pressure.
RESULTS: Least-squares mean HbA1c decreased from baseline by 0.7% and 0.8% in elderly patients receiving alogliptin 12.5 and 25 mg, respectively, and 0.5% and 0.6%, respectively, in younger patients ( P <.001 for both alogliptin doses vs placebo for both age groups P =.70 for 12.5 mg and .68 for 25 mg for differences between age groups). Results were similar for FPG. Incidence of hypoglycemia was 8.3% or less in all alogliptin groups (≤10.5% for placebo), with no apparent difference between elderly and younger patients. Changes in weight were negligible in all treatment groups in both age categories. The safety profiles of alogliptin were similar in the age and dose groups.
CONCLUSION: Alogliptin was effective and well tolerated in the elderly patients enrolled in these studies. Improvements in HbA1c were similar to those seen in younger patients, and no increase in the risk of hypoglycemia, weight gain, or other adverse events was apparent in elderly patients. 相似文献
120.
Adriane R Rosa Ana Cristina Andreazza Fernando Kratz Gazalle Jose Sanchez-Moreno Aida Santin Airton Stein Helena MT Barros Eduard Vieta Flávio Kapczinski 《Clin Pract Epidemiol Ment Health》2006,2(1):34